A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells
- PMID: 11875047
- DOI: 10.1093/hmg/11.5.525
A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells
Abstract
Tuberous sclerosis (TSC) is a autosomal dominant genetic disorder caused by mutations in either TSC1 or TSC2, and characterized by benign hamartoma growth. We developed a murine model of Tsc1 disease by gene targeting. Tsc1 null embryos die at mid-gestation from a failure of liver development. Tsc1 heterozygotes develop kidney cystadenomas and liver hemangiomas at high frequency, but the incidence of kidney tumors is somewhat lower than in Tsc2 heterozygote mice. Liver hemangiomas were more common, more severe and caused higher mortality in female than in male Tsc1 heterozygotes. Tsc1 null embryo fibroblast lines have persistent phosphorylation of the p70S6K (S6K) and its substrate S6, that is sensitive to treatment with rapamycin, indicating constitutive activation of the mTOR-S6K pathway due to loss of the Tsc1 protein, hamartin. Hyperphosphorylation of S6 is also seen in kidney tumors in the heterozygote mice, suggesting that inhibition of this pathway may have benefit in control of TSC hamartomas.
Similar articles
-
A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice.Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8762-7. doi: 10.1073/pnas.151033798. Epub 2001 Jul 3. Proc Natl Acad Sci U S A. 2001. PMID: 11438694 Free PMC article.
-
Estrogen enhances whereas tamoxifen retards development of Tsc mouse liver hemangioma: a tumor related to renal angiomyolipoma and pulmonary lymphangioleiomyomatosis.Cancer Res. 2005 Mar 15;65(6):2474-81. doi: 10.1158/0008-5472.CAN-04-3840. Cancer Res. 2005. PMID: 15781664
-
Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background.J Clin Invest. 1999 Sep;104(6):687-95. doi: 10.1172/JCI7319. J Clin Invest. 1999. PMID: 10491404 Free PMC article.
-
The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.Novartis Found Symp. 2004;262:148-54; discussion 154-9, 265-8. Novartis Found Symp. 2004. PMID: 15562827 Review.
-
The tuberous sclerosis complex (TSC) pathway and mechanism of size control.Biochem Soc Trans. 2003 Jun;31(Pt 3):584-6. doi: 10.1042/bst0310584. Biochem Soc Trans. 2003. PMID: 12773160 Review.
Cited by
-
mTOR signaling in epilepsy: insights from malformations of cortical development.Cold Spring Harb Perspect Med. 2015 Apr 1;5(4):a022442. doi: 10.1101/cshperspect.a022442. Cold Spring Harb Perspect Med. 2015. PMID: 25833943 Free PMC article. Review.
-
Fetal deficiency of lin28 programs life-long aberrations in growth and glucose metabolism.Stem Cells. 2013 Aug;31(8):1563-73. doi: 10.1002/stem.1423. Stem Cells. 2013. PMID: 23666760 Free PMC article.
-
mTORC1 Prevents Preosteoblast Differentiation through the Notch Signaling Pathway.PLoS Genet. 2015 Aug 4;11(8):e1005426. doi: 10.1371/journal.pgen.1005426. eCollection 2015 Aug. PLoS Genet. 2015. PMID: 26241748 Free PMC article.
-
Rapamycin and rapalogs for tuberous sclerosis complex.Cochrane Database Syst Rev. 2016 Jul 13;7(7):CD011272. doi: 10.1002/14651858.CD011272.pub2. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2023 Jul 11;7:CD011272. doi: 10.1002/14651858.CD011272.pub3 PMID: 27409709 Free PMC article. Updated. Review.
-
Inhibition of the glutamine transporter SNAT1 confers neuroprotection in mice by modulating the mTOR-autophagy system.Commun Biol. 2019 Sep 18;2:346. doi: 10.1038/s42003-019-0582-4. eCollection 2019. Commun Biol. 2019. PMID: 31552299 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous